Stevanato Group (NYSE: STVN)
Stevanato Group (NYSE: STVN)
One-line summary: Highest-conviction listed fill-finish/primary container beneficiary of GLP-1 scale — GLP-1 revenue grew >50% in 2025 to 19-20% of total revenue; 2026 mid-teens GLP-1 growth guided.
What it is
Italian glass container and drug delivery systems manufacturer. Makes prefilled syringes, glass vials, and cartridges for injectable drugs (primary containers), plus fill-finish CDMO services. Its Nexa prefilled syringes and EZ-fill cartridges are the highest-value products — specifically designed for GLP-1 biologics requiring specialized handling. NYSE-listed with US liquidity.
Why it matters to stock-market
Every injectable GLP-1 dose needs a primary container. Novo Nordisk's acquisition of three Catalent fill-finish sites ($11B) removed those sites from the independent market — structurally redirecting Lilly and other GLP-1 developers toward Stevanato and Lonza. This is a multi-year structural demand lock created by Novo's captive strategy.
Key facts
- GLP-1 revenue 2025: Grew >50% vs 2024; GLP-1 = ~19-20% of total 2025 revenue. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
- Nexa prefilled syringes: Fastest-growing product, driven primarily by GLP-1. Customer base for high-value prefilled syringes grew >40% in 2025. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
- 2026 guidance: Full-year revenue €1.260–€1.290B; GLP-1 growth "mid-teens" percentage; high-value solutions ~47-48% of revenue. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
- CapEx: €294.9M in 2025 (89% growth-directed); Fishers, Indiana plant targeting commercial activities end-2026 / early 2027. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
- Structural demand shift: Novo Nordisk acquired Catalent's three fill-finish sites → captive to Novo. Eli Lilly CEO publicly complained this could damage competitors' access. Lilly redirects to STVN and Lonza. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
- Injectable dominance: Management projects injectable GLP-1s will remain ~70% of total GLP-1 volume even as oral pills grow. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
Strengths
- Direct beneficiary of Novo's Catalent acquisition redirecting Lilly/other demand to independents
- NYSE-listed (liquid); growing proportion of GLP-1 revenue provides transparent investment thesis
- US manufacturing facility (Indiana) coming online 2026-2027 — further supply chain localization premium
Risks
- Oral GLP-1 risk: if orforglipron captures >30% of market, injectable container demand growth slows (though management guides 70% injectable mix durability)
- Concentrated customer risk: if Novo or Lilly brings fill-finish in-house beyond Catalent, STVN volumes could lag guidance